Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Analysis: U.S. FDA faces mounting criticism over Alzheimer's drug approval

Stock MarketsJun 11, 2021 05:21PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
2/2 © Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo 2/2

By Deena Beasley and Julie Steenhuysen

(Reuters) - In approving the first new Alzheimer's drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.

The Biogen Inc (NASDAQ:BIIB) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of the lethal mind-wasting disease.

The FDA has granted so-called "accelerated approval" in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market.

Aduhelm, however, is in a different league in terms of the number of potential patients and cost to the healthcare system.

In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel's members have resigned in protest since the FDA decision was announced on Monday (NASDAQ:MNDY).

"This decision has shaken the foundations of the scientific process and methods," said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug.

He said the FDA made its decision "by fiat," and had not asked its advisors to consider whether the drug's ability to remove a type of brain plaques known as beta amyloid would improve outcomes for patients.

"It's a disturbing set of events, scientifically, clinically, politically," Karlawish said.

Biogen has said that some 1.5 million Americans with early-stage Alzheimer's will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost.

The FDA approval allows Biogen to sell its product over several years - with forecasts for potential annual sales reaching as high $10 billion to $50 billion - until the company completes a required follow-up study.

"No amount of unmet need can take the place of sufficient evidence," said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.

The number of Americans living with Alzheimer's is expected to more than double to around 13 million by 2050, according to the Alzheimer's Association.

Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion.

"I believe they came to the right decision on behalf of the American public," Sandrock said in an interview.


The FDA has defended its decision by saying that Biogen presented clear evidence that Aduhelm, known chemically as aducanumab, removed beta amyloid from the brains of people with Alzheimer’s.

Amyloid has long been a target of experimental therapies for the disease. However, none of the earlier drugs have shown that reductions in amyloid resulted in significant benefits for patients by slowing deteriorating cognition or ability to function.

Dr. Peter Stein, director of the FDA's Office of New Drugs, told Reuters that Aduhelm showed the clearest correlation so far between a reduction in beta amyloid and a delay in cognitive decline among patients, suggesting it was a good predictor of clinical benefit.

FDA officials said other Alzheimer's drug developers cannot assume their therapies will be considered under the same framework. Eli Lilly (NYSE:LLY) and Co and Roche Holding AG (OTC:RHHVF) are among drugmakers also working on amyloid-targeting medicines.

"We can't say right now whether this will be a path for other Alzheimer's drugs, or drugs for other neurodegenerative diseases," Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, told Reuters.

Critics are less convinced that amyloid removal is an adequate proxy to predict benefit.

"We need to rethink the use of these regulations as interpreted and used by FDA," said Karlawish.

Nearly half of all drugs receiving accelerated approval ultimately got full approval, after a median of around three years, according to a report by the Institute for Clinical and Economic Review (ICER), a drug cost watchdog.

Exceptions include Lilly's Lartruvo for sarcoma, which was withdrawn, while the FDA revoked its authorization for Roche's Avastin to treat breast cancer, although it is still used for other cancers.

More than 100 drugs with accelerated approvals have been on the market a median of just under two years, according to ICER. The report noted that many of the confirmatory trials are slow to complete, and the results often ambiguous.

"The agency has gotten comfortable with the accelerated approval pathway," said attorney Jim Shehan, head of FDA regulatory practice at law firm Lowenstein Sandler.

Biogen has said a confirmatory Aduhelm trial could take nine years to complete. The FDA described that estimate as “conservative” and said it would support “efforts to complete this trial in the shortest possible timeline.”

Despite Aduhelm's high price, patient advocates hailed the FDA decision, saying it will revive research in the field, including the kinds of drug combinations that have improved treatment of complex diseases like cancer and HIV.

"This approval will spark additional investment by other companies in disease-modifying treatments and therapies," advocacy group UsAgainstAlzheimer's said in a statement.

Analysis: U.S. FDA faces mounting criticism over Alzheimer's drug approval

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
Me comment
Me comment Jun 13, 2021 1:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Which pharama company is the FDA payroll paid by.
Ad Cline
Ad Cline Jun 11, 2021 6:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the FDA can no longer be trusted. President Biden needs to clean house at the FDA. The FDA is in the pocket of big pharma.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email